The first step to use engineered MSCs to support a T cell anti-tumor response was most recently reported by Szoor et al. [50] who engineered MSCs to release a bispecific T cell engager and to provide CD80 and 4-1BB costimulation. Here, TNFRSF9 is linked to neoplasm.